^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Drug Class: | FLT3 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE
Excerpt:
...best response obtained according to European Leukemia Net (ELN) 2017 recommendations and ADMIRAL definitions effectiveness will also described in the following subgroups : refractory after 1st line chemo, 1rst relapse = 6 months after CR1, refractory after 1 st relapse salvage treatment, beyond the first relapse (>= 2nd relapse), post Hematopoietic Stem Cell Transplantation (HSCT), post 1L midostaurine and by ELN 2017 risk groups`Gilteritinib effectiveness in FLT3-mutated AML patients in R/R situation...
Trial ID:
Source:
Title:
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
Excerpt:
...- Subject is positive for FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD] [D835/I836] mutation) (or for...
Trial ID:
More C2 evidence
Source:
Title:
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Excerpt:
...- Subject is positive for FLT3 mutation in bone marrow or whole blood as determined by the central lab....
Trial ID:
Source:
Title:
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Excerpt:
...- Participant is positive for FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication [ITD] and/or tyrosine kinase domain [TKD] [D835/I836] mutation) in bone marrow or whole blood as determined by the central laboratory....
Trial ID:
Source:
Title:
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Excerpt:
...- Participant is positive for FLT3 mutation in bone marrow or whole blood as determined by the central lab....
Trial ID:
Source:
Title:
Individual Patient Expanded Access Gilteritinib (ASP2215)
Excerpt:
...Subject has presence of the FLT3 mutation (internal tandem duplication [ITD] and/or tyrosine kinase domain [TKD] [D835/I836] mutation) in bone marrow or peripheral blood as determined by local laboratory....
Trial ID:
Source:
Title:
A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
Excerpt:
...- Subject is positive for FLT3 mutation in bone marrow or blood after completion of the subject's last interventional treatment....
Trial ID:
Source:
Title:
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Excerpt:
...- Subject has presence of the FLT3-mutated relapsed or refractory AML or FLT3-mutated AML in CRc (CR, CRi, CRp) with MRD in bone marrow or peripheral blood....
Trial ID:
Source:
Title:
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Excerpt:
...- Patient has presence of the FLT3 mutation (internal tandem duplication and/or tyrosine kinase domain [D835/I836] mutation) in bone marrow or peripheral blood....
Trial ID:
Source:
Title:
China Children's Leukemia Group (CCLG)-AML2019 supplementary study on pediatric acute myeloid leukemia-Gilteritinib therapy
Excerpt:
...Patients with FLT3-mutated....
Trial ID:
Source:
Title:
A study of Gilteritinib combined with chemotherapy to treat Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML) with a FLT3 gene mutation
Excerpt:
...El sujeto muestra positividad de mutación FLT3/ITD en médula ósea o en sangre en el estudio practicado por el centro local.3. ...
Trial ID:
Less C2 evidence
Source:
Title:
Multi-Modal Targeting of FLT3 with Chimeric Antigen Receptor T Cell Immunotherapy and Tyrosine Kinase Inhibition in High-Risk Pediatric Leukemias
Published date:
11/04/2021
Excerpt:
Taken together, our preclinical studies demonstrate that dual targeting with FLT3CART immunotherapy and gilteritinib is a promising therapeutic strategy in FLT3-mutant AML and, importantly, also in KMT2A-R ALL.
DOI:
10.1182/blood-2021-147321
